HCRN-GI18-333
Phase 2 study of novel SEQUEnced immunotherapy (pembrolizumab) with anti-angiogenesis and chemotherapy in advanced gastric and gastroesophageaL junction (GEJ) adenocarcinoma (SEQUEL)
Status: Open to Accrual
Linked In
You Tube
Phase 2 study of novel SEQUEnced immunotherapy (pembrolizumab) with anti-angiogenesis and chemotherapy in advanced gastric and gastroesophageaL junction (GEJ) adenocarcinoma (SEQUEL)
Status: Open to Accrual
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter